Conversion Notice and Total Voting Rights

SkinBioTherapeutics PLC

12 March 2024

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

Conversion Notice and Total Voting Rights

12 March 2024 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science business focused on skin health, announces that it received a Conversion Notice on 4 March 2024 from Macquarie ("Macquarie") for £80,000 of Convertible Bonds from the £5.0 million convertible bond facility announced on 25 January 2024. The Company has drawn a total of £1,600,000 under the Facility.

SkinBioTherapeutics will issue 1,108,524 ordinary shares of £0.01 per share ("Ordinary Shares") at a conversion price of 7.216800p per Ordinary Share.

Admission and Total Voting Rights

Application has been made for the 1,108,524 new ordinary shares, which will rank pari passu in all respects with the existing ordinary shares of the Company, to be admitted to AIM, which is expected to occur on or around 8.00 a.m. on 14 March 2024 ("Admission"). Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 192,795,949.

The above figure of 192,795,949 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Conversion Update

Purusant to the two previous conversions announced on 9 February 2024 and 28 February 2024, a total of 1,324,484 Ordinary shares have been converted and sold by Macquarie Bank/CLG which represents 13% of all trading volume in the market during the month of February 2024.

Furthermore, Macquarie Bank/CLG have agreed to no further conversions for the month of March unless price and volumes reach certain agreed higher thresholds.

-Ends-

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

For more information please contact: SkinBioTherapeutics plc Stuart J. Ashman, CEO Manprit Randhawa, CFO Tel: [phone] Cavendish Capital Markets Limited (Nominated Adviser & Broker) Giles Balleny, Dan Hodkinson (Corporate Finance) Charlie Combe (Broking) Dale Bellis, Tamar Cranford-Smith (Sales) Tel: [phone] Instinctif Partners (financial press) Melanie Toyne-Sewell / Jack Kincade Tel: [phone] [e-mail]

 Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.

 

END